147P - Midline crossing grade I to grade III gliomas: Impact of high dose XRT on survival
|Date||17 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Central Nervous System Malignancies
Surgery and/or Radiotherapy of Cancer
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix42-ix45. 10.1093/annonc/mdw578|
K. Mushtaq1, S. Butt2, T. Mehmood1
Midline crossing gliomas are known to have a dismal prognosis across the globe. There is a paucity of literature on standard radiotherapy regimens for their management. Our study, primarily, aims to evaluate the significance of escalated radiotherapy doses. In addition, the significance of size and enhancement at initial imaging, as prognostic factors of overall survival.
For our retrospective study, we identified 34 patients with Grade I to III midline crossing gliomas, treated at Shaukat Khanum Memorial hospital, from 2005 till 2010. 22 males and 12 females, aged 23 to 59 years, were randomized into four groups, based on the dose of radiotherapy received. They were 60Gy/30#, 56Gy/28#, 48Gy/16# and 30Gy/10#. Their frequencies were 52.9%, 8.8%, 23.9% and 14.7% respectively. The histologies included were Astrocytomas, Oligodendrogliomas and Ependymomas. With respect to initial tumor size, four groups were identified. Patients with 10-29mm, 30-49mm,50-69mm and 70-90mm tumors. Their respective frequencies were 14.7%,41.2%,17.6% and 26.5%. 55.9% had enhancing tumors and 44.1% had non enhancing tumors. The outcome compared was 5 years overall survival in the four radiotherapy groups. In addition, difference in overall survival, according to tumor size and enhancement at initial imaging, was evaluated.
The overall survival was found to be 36% at 5 years and 18% at 9 years. At 5 years, the overall survival for patients who received 60Gy/30#, 56Gy/28#, 48Gy/16# and 30Gy/10# was found to be 32%, 62%, 22% and 20% respectively. In summary, the overall survival for patients who received >50Gy was 36% as compared to 20% for patients with
The overall survival of patients with midline crossing gliomas is significantly improved with higher radiotherapy doses, while increasing size and enhancement in tumors negatively affect it.
Clinical trial indentification
Legal entity responsible for the study
All authors have declared no conflicts of interest.